This dispatch covers Thymosin Beta-4 in Cardiac Tissue Regeneration in the Healing research category, authored by Garcia, M., Thompson, E., Nakamura, Y., originally published in Cardiovascular Research on January 10, 2024. It has been cited 203 times and takes approximately 18 minutes to read. The Peptide Dispatch curates peer-reviewed peptide research for self-directed learners. All summaries are presented for Research Use Only and do not constitute medical advice.
Across two decades of preclinical work, Thymosin Beta-4 (TB-500) has shown reproducible signal in rodent and porcine cardiac-infarction models: 18-30% smaller scar size, 6-12 percentage-point improvement in left-ventricular ejection fraction, and increased capillary density in the peri-infarct border zone. The proposed mechanism centres on three pathways — actin-cytoskeleton modulation, upregulation of VEGF/MMP-2/ILK, and mobilisation of epicardial-derived progenitor cells. Timing matters: prophylactic and early post-infarction administration produce the largest effects; delayed dosing produces minimal effect. Human data are limited to a single Phase 1 safety study in healthy volunteers (no efficacy endpoint, no cardiovascular-disease cohort). Long-term safety is uncharacterised, and the angiogenic mechanism that drives tissue repair raises theoretical oncological questions that have not been formally addressed. TB-500 is unscheduled by the FDA, prohibited by WADA, and not approved for any clinical indication.
Thymosin Beta-4 (TB-500 in research-grade preparations; the synthetic name commonly used for the 43-amino-acid full-length thymosin beta-4 sequence and for active C-terminal fragments) has emerged over the past two decades as one of the most actively investigated peptides in cardiac regenerative-medicine research. This dispatch synthesises preclinical and early translational findings on TB-500's effects in models of myocardial ischaemia and post-infarction cardiac remodelling, drawing on rodent infarction studies, large-animal cardiac investigations, and the small number of published Phase 1 human safety trials. The biological rationale for studying TB-500 in cardiac repair rests on three converging mechanistic observations. First, TB-500 sequesters G-actin monomers and modulates actin-cytoskeleton dynamics, which is implicated in cell migration — a critical step for cardiac progenitor cells responding to ischaemic injury. Second, the peptide upregulates a constellation of pro-angiogenic factors including VEGF, MMP-2, and integrin-linked kinase, which together drive coronary microvascular regrowth in infarcted tissue. Third, TB-500 has been shown to mobilise epicardial-derived progenitor cells (EPDCs) — a quiescent stem-cell-like population in the adult heart — and promote their migration into damaged myocardium where they can contribute to vascular and, more controversially, cardiomyocyte lineage replacement. The most-cited preclinical evidence comes from murine left-anterior-descending (LAD) coronary-artery ligation models. In a series of studies first published in 2004 and replicated by independent groups in 2007, 2010, and 2014, intraperitoneal TB-500 administration (typically 150-400 ug per dose, three to seven days following infarction) reduced infarct scar size by 18-30% relative to saline controls, improved left-ventricular ejection fraction on echocardiography (mean improvement +6-12 percentage points at 28 days), and was associated with increased CD31-posi…
All information is presented for Research Use Only (RUO). Not medical advice.